To evaluate the efficacy of imatinib in a practical setting, we registered 43 patients with
newly diagnosed chronic myelogenous leukemia (CML)(group I) and 56 patients with …

Imatinib has become standard therapy for patients with chronic myelogenous leukemia
(CML). A complete cytogenetic response can be achieved in 75% to 90% of patients treated …

Although imatinib is considered as a front line therapy in patients with chronic myeloid
leukemia (CML), it is still unclear whether transient imatinib discontinuation may adversely …

Mrs G is a 54-year-old woman with a diagnosis of chronic-phase chronic myeloid leukemia
dating back 8 years. She had a low-risk Sokal score at diagnosis and was started on …

Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly
changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy …

Background Imatinib was the first tyrosine kinase inhibitor that has revolutionized the
therapy of chronic myeloid leukemia. It binds breakpoint cluster region–Abelson kinase …

Imatinib is now established as the gold standard first-line therapy for patients with chronic
myeloid leukemia (CML). Responses to imatinib are superior to those seen with interferon …

Identification of BCR‐ABL as the defining leukemogenic event in chronic myelogenous
leukemia (CML) revolutionized the treatment of the disease. Imatinib, a potent BCR‐ABL …

Second malignant neoplasms are gradually becoming a recognized long‐term complication
of successful cancer treatment, and they usually respond poorly to conventional therapy and …

Objective: The discovery of imatinib was a milestone for chronic myeloid leukemia (CML). As
the life expectancy of CML patients has approached that of the general population, research …